Completion of enrollment for RE-LY the latest milestone in the extensive Phase III clinical trial program is being examined etexilate in more than 34,000 patients for the prevention and treatment of a range of thromboembolic conditions and stroke. Andreas Barner, Member of the Board of Boehringer Ingelheim, responsible for Research, Development and Medicine said: ‘Our investment in landmark trials such as RE-LY Boehringer Ingelheim showing the continuous commitment to improving future treatment options for patients with cardiovascular conditions.

,, Professor of Epidemiology and Cardiology and director of the study coordination center at McMaster University in Hamilton, said: Patient enrollment in RE-LY our original expectations our original expectations by far. .. The RE-LY trial comparing two blinded doses of oral dabigatran etexilate with warfarin in patients with atrial fibrillation who are at moderate to high risk of stroke. Currently, the standard treatment is prevent stroke in these patients , the vitamin K antagonist warfarin. It is estimated that warfarin is for for only half of all eligible patients.Contact, with their Brains, Monkey ‘ Move and Feel Virtual Objectslearned Add to a first demonstration of a two way interaction of a primate brain and a virtual body, are two monkeys at the Duke University the Center for Neuroengineering schooled brain dealing activities solely moved an avatar manual and identification the texture of virtual objects.

Three different Despite virtual objects have been used in the study are identical visually, it several artificial different artificial Texture which only detected when they are investigated be studied with virtual hands of directly controlled by their brain’s electrical activity.. Out moving a part of their real bodies, monkeys used her electric cerebral activity to direct the virtual his hands on the surface of the avatar and virtual objects, in contact, were differentiate their textures.